Statins Don't Cause What You Think They Cause. Except When They Do.

Clinical Takeaway / TL;DR

Domain

Key Finding

Evidence Level

Myopathy

True myopathy (<0.1% on standard doses); rhabdomyolysis ~1–4 per 100,000 patient-years. SAMSON and StatinWISE demonstrate up to 90% of SAMS symptom burden is nocebo-mediated in blinded rechallenge. Genuine intolerance redirects to bempedoic acid (CLEAR Outcomes; MACE ‑13%; Class I ESC/EAS 2025).

N-of-1 RCTs / Large Meta-analysis

Dementia / Cognitive

No FDR-significant signal for cognitive impairment across 19 blinded RCTs (N=123,940; CTT Collaboration 2026). EBBINGHAUS-OLE: no impairment at 7 years with LDL reaching <25 mg/dL. Novak et al. 2026 (N=838,217): 31% lower incident Alzheimer's risk with statin use (RR 0.69). Three independent datasets. Same direction.

Blinded IPD Meta-analysis + Prospective RCT + Real-World Cohort

Cancer

No increased cancer incidence or mortality across 21 RCTs (N=129,526; CTT Collaboration). No confirmed causal mechanism. Emerging observational data suggests possible protective signal for colorectal, endometrial, and aggressive prostate cancer. This fear has no clinical foundation.

Definitive Large-Scale Meta-analysis

Diabetes ⚠

This one is real. ~9–12% relative increase in new-onset T2DM (Sattar et al., Lancet 2010; Preiss et al., JAMA 2011). Higher with intensive therapy. NNT/NNH math strongly favors statins in high-CV-risk patients (~6–7 events prevented per DM case caused). Pitavastatin may be metabolically neutral. Never stop the statin — treat the diabetes.

Replicated Meta-analysis / RCT Data

Statins Don't Cause What You Think They Cause. Except When They Do.

Reply

Keep Reading

Substance Over Noise

Statins Don't Cause What You Think They Cause. Except When They Do.

Subscribe to keep reading

Reply

Keep Reading

Substance Over Noise